Unum Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#1101

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Unum Therapeutics's estimated annual revenue is currently $15.7M per year.(i)
  • Unum Therapeutics received $15.0M in venture funding in March 2017.
  • Unum Therapeutics's estimated revenue per employee is $155,000
  • Unum Therapeutics's total funding is $282.7M.

Employee Data

  • Unum Therapeutics has 101 Employees.(i)
  • Unum Therapeutics grew their employee count by 261% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Unum Therapeutics is a Cambridge, Massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual's cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum's approach is not restricted by antigens and may have applications for treating many types of cancers. Unum's vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. Unum's lead program based on ACTR technology is currently in Phase I clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, Unum is actively working with partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Unum expects to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$282.7M

Total Funding

101

Number of Employees

$15.7M

Revenue (est)

261%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Unum Therapeutics News

2022-04-17 - Global Tumor Immunotherapy Market 2022 Operating ...

... Altor Bioscience Corporation; Cellectis; Juno Therapeutics; Takara Bio; Unum Therapeutics; Sunway; Junshi Bio; Cinda Bio; BeiGene.

2022-04-13 - Cogent Biosciences (NASDAQ:COGT) Upgraded to Hold by ...

It is focused on developing precision therapies for genetically ... Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc.,...

2022-03-30 - Anti-body Coupled T Receptor Therapy Market Showcases ...

... Demand and Improved Supply Chain Ecosystem | Seattle Genetics, Inc. and Unum Therapeutics, Inc. Gilead Lifescience, Inc. Novartis AG,.

2021-04-06 - Cogent Biosciences Announces Creation of Cogent Research Team

BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief ...

2020-12-04 - Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 11,794,872 shares of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.7M10112%$278.9M
#2
$15.7M101-5%N/A
#3
$22.2M101130%$16.9M
#4
$20.8M102-4%N/A
#5
$18.4M1023%N/A

Unum Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-10-22$12.0MAFidelity BiosciencesArticle
2015-06-12$65.0MBNew Leaf Venture PartnersArticle
2017-03-20$15.0MUndisclosedSquare 1 BankArticle